FDA Brief

Warning letters Drugs

FDA warning letter to

Foshan Biours Biosciences Co., Ltd.

High riskIssued Mar 10, 2021Posted Mar 16, 2021Center for Drug Evaluation and Research

Foshan Biours Biosciences, an OTC patch maker, lacked release testing, cleaning validation, and stability data, so FDA says its drugs are adulterated.

What happened

FDA reviewed records the company submitted after FDA's April 3, 2020 request under section 704(a)(4), not an inspection. The records showed the company released an OTC patch for the U.S. without adequate identity and strength testing, had no validated cleaning procedure for non-dedicated equipment, and lacked stability data covering the active ingredient. FDA placed the product on Import Alert 66-40 on October 22, 2020.

What FDA found

  1. The company did not test each batch of its OTC patch for identity and strength of the active ingredient before release.

    21 CFR 211.165(a)
  2. The company had no validated cleaning procedure for non-dedicated equipment used to make and package the OTC patch.

    21 CFR 211.67(b)
  3. The company's stability data for the OTC patch did not test the active ingredient, so it did not show the drug remains stable through expiry.

    21 CFR 211.166(a)

What FDA wants

FDA asks the company to respond in writing within 15 working days with corrective actions and plans for release testing, cleaning validation, and stability testing for all U.S.-imported drug products. FDA also strongly recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC patches from this manufacturer
  • U.S. importers and distributors of its drug products
  • contract manufacturers using non-dedicated equipment

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk